{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05704361",
            "orgStudyIdInfo": {
                "id": "BP42230"
            },
            "secondaryIdInfos": [
                {
                    "id": "2020-004122-33",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 in Participants With Multiple Sclerosis.",
            "officialTitle": "Official Title: A Multiple-Center, Non-randomized, Open-label, Adaptive, Single-Ascending Dose (Part 1 and Part 2) and Multiple-Ascending Dose (Part 3) Parallel, Phase IB Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 Following Intravenous (Part 1) and Subcutaneous Administration (Parts 2 and 3) in Participants With Multiple Sclerosis",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-investigate-the-safety-tolerability-and-processing-by-the-body-of-intravenous-and-subcutaneous-in-participants-with-multiple-sclerosis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-08-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-01-04",
            "studyFirstSubmitQcDate": "2023-01-19",
            "studyFirstPostDateStruct": {
                "date": "2023-01-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-07",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary purpose of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with multiple sclerosis (MS)."
        },
        "conditionsModule": {
            "conditions": [
                "Multiple Sclerosis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 129,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1: Single Ascending Dose (SAD) IV: RO7121932- Dose Escalation Cohorts 1 to 6 and Later Cohorts",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive a single IV dose of RO7121932 on treatment Day 1. The planned starting dose of RO7121932 is 7 milligrams (mg) and will be escalated up to 2000 mg. The maximum dose will not exceed 4000 mg. Doses may be repeated, adjusted downwards, or intermediate doses may be investigated based on emerging data.",
                    "interventionNames": [
                        "Drug: RO7121932 IV - SAD"
                    ]
                },
                {
                    "label": "Part 2: SAD SC: RO7121932- Dose Escalation Cohorts 1 to 2",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive a single SC dose of RO7121932 on treatment Day 1. The planned starting dose of RO7121932 is 70 mg and will be escalated up to 200 mg. Doses may be repeated, adjusted downwards, or intermediate doses may be investigated based on emerging data.",
                    "interventionNames": [
                        "Drug: RO7121932 SC - SAD"
                    ]
                },
                {
                    "label": "Part 3: Multiple Ascending Dose (MAD) SC: RO7121932- Dose Escalation Cohorts 1 to 3",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive multiple SC doses of RO7121932, once weekly on treatment Day 1 through Day 22. The planned starting dose of RO7121932 is 70 mg and will be escalated up to 700 mg. Doses may be repeated, adjusted downwards, or intermediate doses may be investigated based on emerging data.",
                    "interventionNames": [
                        "Drug: RO7121932 - MAD"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "RO7121932 IV - SAD",
                    "description": "Part 1: Participants will receive a single dose of RO7121932 administered as IV infusion.",
                    "armGroupLabels": [
                        "Part 1: Single Ascending Dose (SAD) IV: RO7121932- Dose Escalation Cohorts 1 to 6 and Later Cohorts"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "RO7121932 SC - SAD",
                    "description": "Part 2: Participants will receive a single dose of RO7121932 administered as SC injection.",
                    "armGroupLabels": [
                        "Part 2: SAD SC: RO7121932- Dose Escalation Cohorts 1 to 2"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "RO7121932 - MAD",
                    "description": "Part 3: Participants will receive multiple doses of RO7121932 administered as SC injections.",
                    "armGroupLabels": [
                        "Part 3: Multiple Ascending Dose (MAD) SC: RO7121932- Dose Escalation Cohorts 1 to 3"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part 1, Part 2 and 3: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) with Severity of AEs Measured According to National Cancer Institute Common Terminology Criteria for Adverse Events version 5 (NCI CTCAE v5)",
                    "timeFrame": "Day 1 to Day 169 for part 1 and part 2; Day 1 to Day 197 for part 3"
                },
                {
                    "measure": "Part 1, Part 2 and Part 3: Percentage of Participants With Abnormal Laboratory Findings",
                    "timeFrame": "Day 1 to Day 169 for part 1 and part 2; Day 1 to Day 197 for part 3"
                },
                {
                    "measure": "Part 1, Part 2 and Part 3: Percentage of Participants With Abnormal Vital Signs and Electrocardiogram (ECG) Parameters",
                    "timeFrame": "Day 1 to Day 169 for part 1 and part 2; Day 1 to Day 197 for part 3"
                },
                {
                    "measure": "Part 1, Part 2 and Part 3: Change From Baseline in Suicide Risk as Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)",
                    "description": "The C-SSRS is an interview-based instrument used to assess baseline incidence of suicidal ideation and behavior. The assessment includes \"yes\" or \"no\" responses for 5 questions, each related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings are provided for severity of ideation (if present), from 0 to 5. A score of 0 is assigned if no suicide risk is present. A score of 1 or higher indicates suicidal ideation or behavior, with 5 being the most severe.",
                    "timeFrame": "Day 1 to Day 169 for part 1 and part 2; Day 1 to Day 197 for part 3"
                },
                {
                    "measure": "Part 2 and Part 3: Percentage of Participants with Local Pain at the Site of Injection Assessed Using the Visual Analog Scale (VAS)",
                    "description": "VAS is a 100 millimetre (mm) horizontal visual analog scale with values 0 to 100 mm to indicate pain. The following cutpoints on the pain VAS will be considered in the interpretation of the pain data: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm). A higher score indicates greater pain intensity.",
                    "timeFrame": "Day 1, 2, 5, 8 for part 2; Day 1, 2, 5, 8, 15, 22, 29, 36 for part 3"
                },
                {
                    "measure": "Part 2 and Part 3: Percentage of Participants with Local Injection Site Reaction Using Local Injection-site Symptom Assessment (LISSA)",
                    "description": "LISSA form will be used to assess the participant's injection site for the following categories of reactions: Burning, Itching, Bruising, Erythema (redness), Hive formation, Induration, Swelling, Ecchymosis, Sensitivity, Papules, Stinging, Blister, Cold sensation, and Other. These reactions will be described using the following scale: Unable to assess, less than a dime (\\<18 mm/\\<0.7 inches), a dime (18 mm/0.7 inches), a nickel (21 mm/0.8 inches), a quarter (24 mm/1 inch), a half dollar (31 mm/1.2 inches), larger than a half dollar (\\>31 mm/\\>1.2 inches). A higher score indicate high injection site reactions.",
                    "timeFrame": "Day 1,2, 5, 8 for part 2; Day 1, 2, 5, 8, 15, 22, 29, 36 for part 3"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Part 1, Part 2 and Part 3 (Week 1 and Week 4): Time to Maximum Observed Concentration (Tmax) of RO7121932",
                    "timeFrame": "Day 1 to Day 169 for part 1 and part 2; Days 1, 2, 5 and, 22 for part 3"
                },
                {
                    "measure": "Part 1, Part 2 and Part 3 (Week 1 and Week 4): Maximum Observed Serum Concentration (Cmax) of RO7121932",
                    "timeFrame": "Day 1 to Day 169 for part 1 and part 2; Days 1, 2, 5 and, 22 for part 3"
                },
                {
                    "measure": "Part 1, Part 2 and Part 3 (Week 1 and Week 4): Area Under the Serum Concentration-Time Curve From Time 0 to 168 Hours (h) (AUC0-168h) Postdose",
                    "timeFrame": "Day 1 (predose) to Day 8 (168 hours post-dose) for parts 1, 2, and 3 (Week 1) and Day 22 (predose) to Day 29 (168 hours post-dose) for part 3 (Week 4)"
                },
                {
                    "measure": "Part 1 and Part 2: Area Under the Serum Concentration-Time Curve up to the Last Measurable Concentration (AUClast)",
                    "timeFrame": "Day 1 to Day 169 for part 1 and part 2"
                },
                {
                    "measure": "Part 1 and Part 2: AUC From Time 0 to Infinity (AUCinf)",
                    "timeFrame": "Day 1 to Day 169 for part 1 and part 2"
                },
                {
                    "measure": "Part 1: Total Body Clearance (CL) Of RO7121932",
                    "timeFrame": "Day 1 to Day 169"
                },
                {
                    "measure": "Part 2 and Part 3 (Week 4): Apparent Clearance (CL/F) of RO7121932",
                    "timeFrame": "Day 1 to Day 169 for part 2; Day 22 to Day 29 for part 3"
                },
                {
                    "measure": "Part 1, Part 2 and Part 3: Terminal Rate Constant of RO7121932",
                    "timeFrame": "Day 1 to Day 169 for part 1 and part 2; Day 22 to Day 197 for part 3"
                },
                {
                    "measure": "Part 1, Part 2 and Part 3: Apparent Terminal Half-Life (T1/2) of RO7121932",
                    "timeFrame": "Day 1 to Day 169 for part 1 and part 2; Day 22 to Day 197 for part 3"
                },
                {
                    "measure": "Part 3: Trough Concentrations (Ctrough) of RO7121932",
                    "timeFrame": "Day 1 to Day 197"
                },
                {
                    "measure": "Part 1 and Part 3: Cerebrospinal Fluid (CSF) Concentration of RO7121932",
                    "timeFrame": "Screening, Day 2 to Day 169 for part 1; Screening, Day 2 to Day 197 for part 3"
                },
                {
                    "measure": "Part 1, Part 2 and Part 3: Percentage of Participants With Anti-RO7121932 Antibodies",
                    "timeFrame": "Predose on Day 1, and on Days 8, 22, 29, 57, 85, 169 for part 1; Predose on Day 1, and on Days 8, 22, 57, 85, 169 for part 2 Predose on Days 1, 8, 15, 22, and on Days 29, 57, 85, 120, 197 for part 3"
                },
                {
                    "measure": "Part 1, Part 2 and Part 3: Time Course of B-cell Frequencies in Blood",
                    "timeFrame": "Screening, Days 1, 2, 8, 22, 57, 85, 169 for part 1; Screening, Days 1, 2, 8, 22, 57, 85, 169 for part 2; Screening, Days 1, 2, 8, 15, 22, 57, 85, 120, 197 for part 3"
                },
                {
                    "measure": "Part 1 and Part 3: Time Course of B-cell Frequencies in CSF",
                    "timeFrame": "Screening, Day 2 to 169 for part 1; Screening, Day 2 to 197 for part 3"
                },
                {
                    "measure": "Part 1, Part 2 and Part 3: Change From Baseline in B-cell Frequencies in Blood",
                    "timeFrame": "Screening, Days 1, 2, 8, 22, 57, 85, 169 for part 1; Screening, Days 1, 2, 8, 22, 57, 85, 169 for part 2; Screening, Days 1, 2, 8, 15, 22, 57, 85, 120, 197 for part 3"
                },
                {
                    "measure": "Part 1 and Part 3: Change From Baseline in B-cell Frequencies in CSF",
                    "timeFrame": "Screening, Day 2 to 169 for part 1; Screening, Day 2 to 197 for part 3"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Expanded Disability Status Scale (EDSS) score \u22647.0 at Screening\n* Participants with relapsing multiple sclerosis (RMS) or progressive multiple sclerosis (PMS) who fulfil international panel criteria for diagnosis (McDonald 2017 criteria)\n* Participants not treated with any approved MS treatment at Screening and not planning to start on any MS therapy during the study (including follow-up)\n* Female participants must practice abstinence or otherwise use contraception\n\nExclusion Criteria:\n\n* Evidence of clinical disease activity as defined by any clinical relapse within 3 months prior to screening, or by \\>1 clinical relapse within 12 months prior to screening\n* Evidence of magnetic resonance imaging (MRI) activity as defined by the presence of \u2265 1 Gadolinium-enhancing T1 lesion in the screening MRI scan or by \u2265 4 new or enlarging T2 lesions in the screening scan as compared to a reference scan\n* Participants who have active progressive multifocal leukoencephalopathy (PML), have had confirmed PML, or have a high degree of suspicion for PML\n* Known presence of other neurological disorders that may mimic MS including but not limited to: neuromyelitis optica spectrum disease, Lyme disease, untreated Vitamin B12 deficiency, neurosarcoidosis, cerebrovascular disorders, and untreated hypothyroidism\n* Known active or uncontrolled bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds, including participants exhibiting symptoms consistent with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within 6 weeks prior to Day 1\n* Participants with a current diagnosis of epilepsy\n* Clinically significant cardiac, metabolic, hematologic, hepatic, immunologic, urologic, endocrinologic, neurologic, pulmonary, psychiatric, dermatologic, allergic, renal, or other major diseases\n* History of cancer, including hematologic malignancy and solid tumors, within 10 years of screening. Basal or squamous cell carcinoma of the skin that has been excised and is considered cured and in situ carcinoma of the cervix treated with apparent success by curative therapy \\>1 year prior to screening is not exclusionary\n* Any concomitant disease that may require treatment with systemic corticosteroids or immunosuppressants during course of the study\n* History of currently active primary or secondary (non-drug-related) immunodeficiency\n* History of hypersensitivity to biologic agents or any of the excipients in the formulation\n* Only for cohorts where CSF samples are planned to be collected: Participants with a history of spinal cord compression, raised intra-cerebral pressure, clinically significant vertebral joint pathology or any other current abnormalities in the lumbar region which could prevent the lumbar puncture procedure.\n\nPrior/Concomitant Therapy:\n\n* Treatment with any approved MS treatment at Screening. Participants may become eligible after completion of a washout period prior to acquiring any screening laboratory tests but should not be withdrawn from therapies for the sole purpose of meeting eligibility for the trial\n* Previous treatment with RO7121932, alemtuzumab, cladribine, mitoxantrone, cyclophosphamide, total body irradiation, bone marrow transplantation, and hematopoietic stem cell transplantation. For the USA only, previous treatment with daclizumab\n* Previous treatment with anti-CD20 B-cell-depleting therapies (e.g., rituximab, ocrelizumab, or ofatumumab)\n\n  * \\<12 months prior to acquiring any screening laboratory tests,\n  * \u226512 months prior to acquiring any screening laboratory tests, if B-cells are outside the normal range, or not back to individual baseline \u00b1 20% (if data are available),\n  * If discontinuation of a prior B-cell depletion therapy was motivated by safety reasons\n* Current or prior treatment with natalizumab (if \\<24 months prior to acquiring any screening laboratory tests)\n\nPrior/Concurrent Clinical Study Experience:\n\n- Participation in an investigational drug medicinal product or medical device study within 30 days before Screening or within five times the pharmacodynamic (PD) or pharmacokinetic (PK) half-life (if known), whichever is longer\n\nDiagnostic Assessments:\n\n* Positive result on human immunodeficiency virus (HIV1) and HIV2, hepatitis C, or hepatitis B\n* Participants with suicidal ideation or behavior within 6 months prior to Screening or participants who, in the Investigator's judgment, pose a suicidal or homicidal risk\n* Vaccination with a live or live-attenuated vaccine within 6 weeks prior to Day 1",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Reference Study ID Number: BP42230 https://forpatients.roche.com/",
                    "role": "CONTACT",
                    "phone": "888-662-6728 (U.S. Only)",
                    "email": "global-roche-genentech-trials@gene.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trials",
                    "affiliation": "Hoffmann-La Roche",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford University Medical Center; Stanford Neuroscience Health Center",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Stanford",
                    "state": "California",
                    "zip": "94305",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.42411,
                        "lon": -122.16608
                    }
                },
                {
                    "facility": "Yale University Multiple Sclerosis Center",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06473",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "University of South Florida",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "University of Massachusetts Medical School",
                    "status": "RECRUITING",
                    "city": "Worcester",
                    "state": "Massachusetts",
                    "zip": "01655",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.26259,
                        "lon": -71.80229
                    }
                },
                {
                    "facility": "UC Health, LLC.",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45219",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "UZ Gent",
                    "status": "RECRUITING",
                    "city": "Gent",
                    "zip": "9000",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 51.05,
                        "lon": 3.71667
                    }
                },
                {
                    "facility": "Montreal Neurological Institute and Hospital; Pharmacy Department",
                    "status": "RECRUITING",
                    "city": "Montreal",
                    "state": "Quebec",
                    "zip": "H3A 2B4",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Universit\u00e4tsklinikum \"Carl Gustav Carus\"; MS Center Dresden",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Dresden",
                    "zip": "01307",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.05089,
                        "lon": 13.73832
                    }
                },
                {
                    "facility": "Universit\u00e4tsmedizin G\u00f6ttingen Georg-August-Universit\u00e4t; Klinik f\u00fcr Neurologie",
                    "status": "RECRUITING",
                    "city": "G\u00f6ttingen",
                    "zip": "37075",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.53443,
                        "lon": 9.93228
                    }
                },
                {
                    "facility": "Klinikum rechts der Isar der TU Muenchen; Neurologische Klinik und Poliklinik im Neuro-Kopf-Zentrum",
                    "status": "RECRUITING",
                    "city": "M\u00fcnchen",
                    "zip": "81675",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 48.13743,
                        "lon": 11.57549
                    }
                },
                {
                    "facility": "Universit\u00e4tsklinikum M\u00fcnster Klinik u. Poliklinik f. Neurologie",
                    "status": "RECRUITING",
                    "city": "M\u00fcnster",
                    "zip": "48149",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.96236,
                        "lon": 7.62571
                    }
                },
                {
                    "facility": "Hadassah University Hospital - Ein Kerem",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Jerusalem",
                    "zip": "9112001",
                    "country": "Israel",
                    "geoPoint": {
                        "lat": 31.76904,
                        "lon": 35.21633
                    }
                },
                {
                    "facility": "Tel Aviv Sourasky Medical Center; Department of Neurology",
                    "status": "WITHDRAWN",
                    "city": "Tel Aviv",
                    "zip": "6423906",
                    "country": "Israel",
                    "geoPoint": {
                        "lat": 32.08088,
                        "lon": 34.78057
                    }
                },
                {
                    "facility": "IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla",
                    "status": "RECRUITING",
                    "city": "Milano",
                    "state": "Lombardia",
                    "zip": "20132",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.46427,
                        "lon": 9.18951
                    }
                },
                {
                    "facility": "Fond. Istituto Neurologico C.Besta; UO Neurologia IV - Neuroimmunologia Malattie Neuromuscolari",
                    "status": "RECRUITING",
                    "city": "Milano",
                    "state": "Lombardia",
                    "zip": "20133",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.46427,
                        "lon": 9.18951
                    }
                },
                {
                    "facility": "ARENSIA Exploratory Medicine Phase I, PMSI Republican Clinical Hospital",
                    "status": "RECRUITING",
                    "city": "Chisinau",
                    "zip": "MD-2025",
                    "country": "Moldova, Republic of",
                    "geoPoint": {
                        "lat": 47.00556,
                        "lon": 28.8575
                    }
                },
                {
                    "facility": "Uniwersyteckie Centrum Kliniczne; Osrodek Badan Wczesnych Faz",
                    "status": "WITHDRAWN",
                    "city": "Gda?sk",
                    "zip": "80-214",
                    "country": "Poland"
                },
                {
                    "facility": "Regionalny Szpital Specjalistyczny im. W. Bieganskiego; Oddzial Neurologiczny",
                    "status": "COMPLETED",
                    "city": "Grudzi?dz",
                    "zip": "86-300",
                    "country": "Poland"
                },
                {
                    "facility": "MedPolonia",
                    "status": "RECRUITING",
                    "city": "Poznan",
                    "zip": "60-693",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 52.40692,
                        "lon": 16.92993
                    }
                },
                {
                    "facility": "Osrodek Badan Klinicznych Euromedis",
                    "status": "RECRUITING",
                    "city": "Szczecin",
                    "zip": "70-111",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 53.42894,
                        "lon": 14.55302
                    }
                },
                {
                    "facility": "Instytut Psychiatrii i Neurologii II Klinika Neurologiczna",
                    "status": "WITHDRAWN",
                    "city": "Warszawa",
                    "zip": "02-957",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 52.22977,
                        "lon": 21.01178
                    }
                },
                {
                    "facility": "SPSK nr 1; Klinika Neurologii",
                    "status": "RECRUITING",
                    "city": "Zabrze",
                    "zip": "41-800",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 50.32492,
                        "lon": 18.78576
                    }
                },
                {
                    "facility": "Hospital de Braga; Centro Cl\u00ednico Acad\u00e9mico (Piso 1, Ala E)",
                    "status": "RECRUITING",
                    "city": "Braga",
                    "zip": "4710-243",
                    "country": "Portugal",
                    "geoPoint": {
                        "lat": 41.55032,
                        "lon": -8.42005
                    }
                },
                {
                    "facility": "ARENSIA Exploratory Medicine, County Emergency Hospital",
                    "status": "RECRUITING",
                    "city": "Cluj-Napoca",
                    "zip": "400006",
                    "country": "Romania",
                    "geoPoint": {
                        "lat": 46.76667,
                        "lon": 23.6
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009103",
                    "term": "Multiple Sclerosis"
                },
                {
                    "id": "D000012598",
                    "term": "Sclerosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000020278",
                    "term": "Demyelinating Autoimmune Diseases, CNS"
                },
                {
                    "id": "D000020274",
                    "term": "Autoimmune Diseases of the Nervous System"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000003711",
                    "term": "Demyelinating Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12060",
                    "name": "Multiple Sclerosis",
                    "asFound": "Multiple Sclerosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15415",
                    "name": "Sclerosis",
                    "asFound": "Sclerosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22098",
                    "name": "Demyelinating Autoimmune Diseases, CNS",
                    "relevance": "LOW"
                },
                {
                    "id": "M22094",
                    "name": "Autoimmune Diseases of the Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M6909",
                    "name": "Demyelinating Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        }
    },
    "hasResults": false
}